Eyepoint, Inc. · NASDAQ:EYPT
Eyepoint — Investor Presentation (April 2026)
26 slides from Eyepoint's investor presentation, Apr 13, 2026
Slide 1: Investor Presentation April 2026
Investor Presentation April 2026 Exhibit 99.1
Slide 2: Legal Disclaimers
Legal Disclaimers Various statements made in this presentation are forward-looking, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, even
Slide 3: A Leader in Sustained Release Drug Delivery for Retinal Disease
A Leader in Sustained Release Drug Delivery for Retinal Disease 1. As of March 31, 2026. Unaudited estimate. AMD, age-related macular degeneration; DME, diabetic macular edema; IVT, intravitreal DURAVYUTM has been conditionally accepted by the FDA as the proprietary name for DURAVYU. DURAVYU is an i
Slide 4: DURAVYU in Phase 3 Trials For the Two Largest Retinal Disease Markets
DURAVYU™ in Phase 3 Trials For the Two Largest Retinal Disease Markets AMD, wet age-related macular degeneration; DME, diabetic macular edema; PK, pharmacokinetics Durasert E™ Programs Indication Discovery Pre-Clin Phase 1 Phase 2 Phase 3 Anticipated Milestone DURAVYU™ (vorolanib intravitreal insert
Slide 5: Products Addressing Unmet Needs Capture Meaningful Share in $15B Anti-VEGF Market
1. Publicly reported sales; 2. Lucentis package insert; 3. Khanani et. al, The Real-World Efficacy and Safety of Faricimab in Neovascular Age Related Macular Degeneration: TRUCKEE Study – 2 Year Results VEGF, vascular endothelial growth factor. Products Addressing Unmet Needs in Retinal Disease Capt
Slide 6: Longer Duration and New MOA are Key Unmet Needs in Current Retinal Disease Treatment
Longer Duration and New MOA are Key Unmet Needs in Current Retinal Disease Treatment Paradigm Insert not drawn to scale and is enlarged for illustrative purposes. The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection. MOA, mechanism of action; IL-6, inter
Slide 7: Vorolanib Features a Multi-MOA, Addressing Both Vascular Leakage and Inflammation
Vorolanib Features a Multi-MOA, Addressing Both Vascular Leakage and Inflammation Data on file. Bakri SJ, et al. PLoS One. 2024;19(6):e0304782. IL-6 (R), interleukin 6 (receptor); JAK, janus kinase; MOA, mechanism of action; PDGF(R), platelet-derived growth factor (receptor); PLGF, placental growth
Slide 8: Durasert E: A Next Generation in Sustained-Release Intravitreal Drug Delivery
Durasert E™: A Next Generation in Sustained-Release Intravitreal Drug Delivery Vitrasert® (ganciclovir IVT)1,a Retisert® (fluocinolone acetonide)2 ILUVIEN® (fluocinolone acetonide)3 YUTIQ® (fluocinolone acetonide)4 DURAVYU™ (vorolanib IVT insert; f/k/a EYP-1901) APPROVED NONERODIBLE | Durasert® INVE
Slide 9: DURAVYU: Best-in-Class TKI for Retinal Disease
DURAVYU™: Best-in-Class TKI for Retinal Disease Insert not drawn to scale and is enlarged for illustrative purposes. The investigational dose for phase 3 trials is 2.7mg (two inserts) administered with one injection. a. Data from preclinical studies. Following a single DURAVYU 900 µg dose in Dutch-B
Slide 10: DURAVYU Has Demonstrated Robust Efficacy Outcomes and a Positive Safety Profile
DURAVYU Has Demonstrated Robust Efficacy Outcomes and a Positive Safety Profile Across Multiple Indications 1. EyePoint. Press release November 19, 2025: EyePoint Announces Positive Recommendation from Independent Data Safety Monitoring Committee for Pivotal Phase 3 Trials for DURAVYU™ in Wet Age-Re
Slide 11: DURAVYU for Wet AMD
DURAVYU for Wet AMD POSITIONED TO BE FIRST TO MARKET AMONG ALL INVESTIGATIONAL Sustained Delivery Therapies WITH A Potential BEST-IN-CLASS Profile
Slide 12: LUGANO and LUCIA: Clinically Rigorous, De-risked Phase 3 Wet AMD Program
LUGANO and LUCIA: Clinically Rigorous, De-risked Phase 3 Wet AMD Program Following Established Non-Inferiority Regulatory Path & Both trials fully enrolled at industry-leading pace Topline 56-week data expected for LUGANO mid-2026; LUCIA anticipated shortly after Key Elements of Phase 3 Trial Design
Slide 13: Phase 3 Pivotal Trials in Wet AMD: Trial Design
Phase 3 Pivotal Trials in Wet AMD: Trial Design Following an Established Non-Inferiority Regulatory Pathway DURAVYU dosing consists of 2 inserts delivered in a single injection. AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; D, day; W, week; EOS, end-of-study; q6M, every
Slide 14: DAVIO 2 Results: All Primary and Secondary Endpoints Were Achieved
DURAVYU Phase 3 Trials in Wet AMD Supported by DAVIO 2 Results: All Primary and Secondary Endpoints Were Achieved DAVIO 2 Endpoints in Wet AMD* 2mg 3mg R Primary: Statistically significant non-inferior change in BCVA vs. aflibercept - 0.3 letters - 0.4 letters R Secondary: Change in BCVA vs. baselin
Slide 15: Subgroup analysis of DAVIO 2 patients eligible for Phase 3
DURAVYU in Wet AMD: Subgroup analysis of DAVIO 2 patients eligible for Phase 3 demonstrates favorable outcomes adding confidence to the Phase 3 plan Data on file. Data includes patients in DAVIO 2 with baseline BCVA of 35-78 letters. BCVA, best-corrected visual acuity; CST, central subfield thicknes
Slide 16: Lower Supplemental Injection Rate Under Stricter Phase 3 Criteria
Data on file. Percentage of Supplemental Treatment Up To Week 32 Patients who met supplemental treatment criteria or received supplemental treatment, % Received/criteria met in DAVIO 2 Adjusted to Phase 3 criteria Outcomes from this analysis builds confidence in Phase 3 Pivotal program DURAVYU in We
Slide 17: New Commercial Manufacturing Facility to Support DURAVYU Through Potential NDA Approval
New Commercial Manufacturing Facility to Support DURAVYU Through Potential NDA Approval and U.S. Commercial Launch NDA, New Drug Application; FDA, Food and Drug Administration; EMA, European Medicines Agency USA based in Northbridge, MA Built to US FDA and EU EMA standards DURAVYU registration batch
Slide 18: DURAVYU for DME
DURAVYU for DME Phase 3 program underway in second largest retinal disease market
Slide 19: COMO and CAPRI: Phase 3 DME Program
COMO and CAPRI: Phase 3 DME Program Designed to Enable Global Regulatory and Commercial Success Global, randomized, double-masked, aflibercept controlled Identical non-inferiority trials vs. on-label aflibercept First patients dosed in both trials in February 2026; full enrollment expected 3Q 2026 K
Slide 20: Phase 3 Pivotal Trials in DME: Non-Inferiority vs On-Label Aflibercept
Phase 3 Pivotal Trials in DME: Designed to Evaluate Non-Inferiority of DURAVYU vs On-Label Aflibercept Control D1 W4 W8 W12 W161 W20 W24 W28 W32 W36 W40 W44 W48 W52 W56 W60 to W68 W72 W76 to W84 W88 EOS Primary endpoint Blend W52 & W56 DURAVYU 2.7 mg Aflibercept 2 mg q8W DURAVYU dosing DURAVYU dosin
Slide 21: Single DURAVYU 2.7mg Treatment Demonstrated Vision and Anatomical Improvement as Early as Week 4
Single DURAVYU 2.7mg Treatment Demonstrated Meaningful Vision and Anatomical Improvement as Early as Week 4 BCVA, best-corrected visual acuity; CST, central subfield thickness; ETDRS, Early Treatment Diabetic Retinopathy Study;. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file. Mean C
Slide 22: BCVA: VERONA DME Results Superimposed on BARDENAS Phase 2 Trial
BCVA: VERONA DME results superimposed on BARDENAS Phase 2 Trial of anti-IL6 (vamikibart) DURAVYU 2.7mg in Supplement-Free Eyes Achieved Similar BCVA as Anti-VEGF + Anti-IL-6 Dosed Monthly BARDENAS Phase 2 clinical trial results adapted from Roche’s Pharma Day presentation, September 22, 2025 [Availa
Slide 23: Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection in DME
Dose-Dependent Reduction in Macular Leakage Area with a Single DURAVYU Injection in DME 1. Change from baseline in vascular leakage (mm2) in the macula and in the total retinal area. Full analysis set. DME, diabetic macular edema. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on file. Vasc
Slide 24: Continued Drying and Improved BCVA After a Single DURAVYU 2.7mg Dose
Continued Drying at Week 24 with Improved BCVA After a Single DURAVYU 2.7mg Dose and No Supplementation BCVA, best-corrected visual acuity; CST, central subfield thickness; D, day; VA, visual acuity; VEGF, vascular endothelial growth factor. VERONA Clinicaltrials.gov Identifier: NCT06099184. Data on
Slide 25: DURAVYU: Potential to be the First and Best in Class TKI in Largest Retinal Disease Indications
DURAVYU™: Potential to be the First and Best in Class TKI in Largest Retinal Disease Indications Vorolanib, a multi-MOA TKI with 6-month durability Robust Phase 1 and 2 efficacy data in wet AMD and DME Favorable safety and tolerability with no safety signals across four clinical trials Topline data
Slide 26: Investor Presentation April 2026
Investor Presentation April 2026